Also known as: MSK
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology, effective July 1, 2026. She is an Attending Physician and Clinic Director at Memorial Sloan Kettering Cancer Center.
Insilico Medicine and Memorial Sloan Kettering Cancer Center have entered a collaborative research agreement to discover new therapeutic targets for gastroesophageal malignancies using AI-powered platforms and extensive multi-omic clinical datasets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07776613 |
A Study of Romosozumab in People With Breast Cancer and Osteoporosis |
RECRUITING | PHASE2 |
| NCT07768449 |
A Study of Counseling Support for Cancer Survivors Age 65+ |
RECRUITING | NA |
| NCT07768436 |
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer |
RECRUITING | PHASE2 |
| NCT07751159 |
Radiation Therapy Approaches for People With Prostate Cancer |
RECRUITING | PHASE2 |
| NCT07725497 |
A Study of Luspatercept in People With Anemia |
RECRUITING | PHASE2 |
| NCT07701733 |
A Study of Lung Cancer Risk |
RECRUITING | |
| NCT07698899 |
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) |
RECRUITING | PHASE1 |
| NCT07691489 |
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07690917 |
A Study of a New PET Scanner in People With Cancer |
RECRUITING | |
| NCT07671339 |
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer |
RECRUITING | PHASE1 |
